Testing mirikizumab in healthy volunteers
Treatments studied
This study is testing a new medicine called mirikizumab in healthy people to see how it works in the body. Healthy volunteers help researchers understand the drug's safety before it is studied in patients with a disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be generally healthy, based on a medical check-up and lab tests.
- Your body mass index (BMI) must be between 18.0 and 34.0.
- You cannot have any major allergies to medicines like mirikizumab.
- You cannot have a weakened immune system or an active infection.
- You must not have taken any other biologic drugs in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called MK-1406 in healthy volunteers to make sure it's safe before it can be studied in patients. If you're generally healthy, you could help advance medical research.
This trial tests a medication called Mirikizumab for adults over 60 with moderate to severe Crohn's disease or ulcerative colitis. It aims to see if the drug is safe and effective for older adults with these conditions.
This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
This study follows people with ulcerative colitis who are starting or have just started mirikizumab treatment. It aims to understand how well the drug works in real-world settings and how patients do over the next 12 months.
This study measures how much of the medication mirikizumab passes into breast milk when mothers take it for their approved medical condition. The goal is to understand if it's safe for breastfeeding infants when mothers are receiving this treatment.
Hear when a new Healthy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.